Comparative Pharmacology
Head-to-head clinical analysis: NABUMETONE versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NABUMETONE versus PROFENAL.
NABUMETONE vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA), is responsible for its therapeutic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
1000 mg orally once daily with food; may increase to 1500-2000 mg/day in divided doses if needed.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Clinical Note
moderateNabumetone + Gatifloxacin
"Nabumetone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNabumetone + Rosoxacin
"Nabumetone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNabumetone + Levofloxacin
"Nabumetone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNabumetone + Trovafloxacin
"Nabumetone may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 22-30 hours in healthy adults, allowing once-daily dosing. Steady state is achieved after 3-5 days.
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Approximately 80% of a dose is excreted in urine as metabolites (primarily 6-methoxy-2-naphthylacetic acid and its glucuronide conjugates), with about 10% excreted in feces. Biliary excretion is minimal.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category D/X
Category C
NSAID
NSAID